Sandbox vidit2

Jump to navigation Jump to search
 
 
 
 
 
 
 
Newly discovered AF
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Paroxysmal
 
 
 
 
 
 
 
Persistent
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Look for the presence of one of these severe symptoms
Hypotension
Heart failure
Angina pectoris

Severe symptoms absent:
No therapy needed


Severe symptoms present:

Attempt direct-current cardioversion
 
 
 
 
Permanent AF
 
 
 
Anticoagulation as needed based on the risk of stroke
Click here for the risk of stroke and anticoagulation therapy
Control heart rate as an intial method to terminate AF
Click here for recommended pharmacological agents used for rate control
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Anticoagulation as needed based on the risk of stroke
Click here for the risk of stroke and anticoagulation therapy
Recommended in all cases except lone AF (I A)
Measure INR weekly initially, then monthly when stable (I A)
Reassess need for anticoagulation at periodic intervals (IIa C)
 
 
 
 
Anticoagulation as needed based on the risk of stroke
Click here for the risk of stroke and anticoagulation therapy
Control heart rate as an intial method to terminate AF
Click here for recommended pharmacological agents used for rate control
 
 
 
Consider antiarrythmic therapy for maintenance of sinus rhythm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Attempt cardioversion
Click here for drugs and doses used for pharmacological cardioversion
If patient hemodynamically unstable or tachycardic attempt electric cardioversion
If pharmacological cardioversion fails attempt electric cardioversion
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Do not treat with long term antiarrythmic therapy, unless indicated.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Antiarrhythmic Drug Therapy in Atrial Fibrillation

Shown below is an algorithm depicting the antiarrhythmic drug therapy for maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial fibrillation:

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maintenance of sinus rhythm
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No (or minimal) heart disease
 
 
 
 
 
Hypertension
 
 
 
 
 
Coronary artery disease
 
 
 
Heart failure
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dronedarone
Flecainide
Propafenone
Sotalol
 
 
 
 
 
Substantial LVH
 
 
 
 
 
Dronedarone
Dofetilide
Sotalol
 
 
 
Amiodarone
Dofetilide
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amiodarone
Dofetilide
 
Catheter ablation
 
No
 
Yes
 
Amiodarone
 
Catheter ablation
 
Catheter ablation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dronedarone
Flecainide
Propafenone
Sotalol
 
Amiodarone
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Catheter ablation
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Amiodarone
Dofetilide
 
Catheter ablation
 
 
 
 
 
 
 
 

Drugs are listed alphabetically and not in order of suggested use.
The seriousness of heart disease progresses from left to right, and selection of therapy in patients with multiple conditions depends on the most serious condition present.
LVH indicates left ventricular hypertrophy.
Algorithm based on the 20011 ACCF/AHA/HRS updates for the management of atrial fibrillation.[1]


  • Dabigatran may be used as an alternative to warfarin in those wdo don't have: (I B)
  • Prosthetic heart valve
  • Hemodynamically significant valve disease
  • Severe renal failure (creatinine clearance <15 mL/min) or
  • Advanced liver disease (impaired baseline clotting function).
  • If patient on anticoagulants with AF sustains stroke or systemic embolism, target INR may be raised to 3.0 - 3.5 (IIb C).
  • Anticoagulation therapy can be interrupted for upto 1 week, if patients needs a procedure that carries a risk of bleeding (IIa C). For periods > 1 week unfractionated or low molecular weight heparin may be given IV (IIb C).
  1. Fuster, V.; Rydén, LE.; Cannom, DS.; Crijns, HJ.; Curtis, AB.; Ellenbogen, KA.; Halperin, JL.; Kay, GN.; Le Huezey, JY. (2011). "2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines". Circulation. 123 (10): e269–367. doi:10.1161/CIR.0b013e318214876d. PMID 21382897. Unknown parameter |month= ignored (help)